Dr. Reddy’s Laboratories has received Health Canada approval to market a generic version of Ozempic, a leading medication for obesity and diabetes. This marks a significant step towards increased affordability for Canadian patients.

Generic Ozempic Approved in Canada

The authorization comes nearly four months after generic Ozempic was legally permissible in Canada. This approval is expected to lower costs by as much as 65%, benefiting both patients and healthcare systems.

Semaglutide and Market Impact

Health Canada confirmed the issuance of a notice of compliance to Dr. Reddy’s for an injectable form of semaglutide, the active ingredient in both Ozempic and Wegovy. Ozempic, manufactured by Novo Nordisk, had Canadian sales exceeding $2.9 billion in 2025, according to IQVIA Canada.

Addressing Affordability Concerns

Stephen Glazer, medical director at Hennick Humber Hospital in Toronto, called the approval “monumental” for Canadians struggling with obesity. He noted that over half of his patients discontinue GLP-1 drugs, including Ozempic, due to cost.

Patient Perspective

Virginia MacKinnon, a retired social worker from Sault Ste. Marie, expressed hope that generics will ease the financial burden of her semaglutide treatment. She currently pays over $100 monthly, with 75% coverage from her benefits plan.

Pricing and Future Availability

The pan-Canadian Pharmaceutical Alliance framework indicates the initial cost of generic Ozempic will be 75% of the brand-name price, potentially dropping to 35% with more manufacturers. Six other drug makers have pending applications for generic semaglutide.

Health Canada’s Review Process

Health Canada confirmed the drug’s approval followed a thorough review of its safety, efficacy, and quality. Dr. Reddy’s submitted its application in February 2024, and the agency met its 180-day approval target.